{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T04:24:03Z","timestamp":1742963043147,"version":"3.40.3"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","jtcvsonline.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jtcvs.2024.10.040","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T04:34:11Z","timestamp":1730349251000},"page":"1098-1099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Commentary: Blood biomarkers: Barriers and benefits"],"prefix":"10.1016","volume":"169","author":[{"given":"Rebecca","family":"Bellis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Cranwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtcvs.2024.10.040_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2016.12.004","article-title":"Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment","volume":"152","author":"Creaney","year":"2017","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jtcvs.2024.10.040_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.jtcvs.2024.10.040_bib3","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1158\/2326-6066.CIR-22-0840","article-title":"Tumor-targeted nonablative radiation promotes solid tumor CAR T-cell therapy efficacy","volume":"11","author":"Quach","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"10.1016\/j.jtcvs.2024.10.040_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026722","article-title":"An in\u00a0vivo platform for tumor biomarker assessment","volume":"6","author":"Servais","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jtcvs.2024.10.040_bib5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s43018-023-00573-4","article-title":"c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation","volume":"4","author":"Xiong","year":"2023","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.jtcvs.2024.10.040_bib6","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.athoracsur.2017.06.042","article-title":"Soluble mesothelin-related peptides to monitor recurrence after resection of pleural mesothelioma","volume":"104","author":"Burt","year":"2017","journal-title":"Ann Thorac Surg"},{"issue":"10272","key":"10.1016\/j.jtcvs.2024.10.040_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jtcvs.2024.10.040_bib8","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jtcvs.2024.10.005","article-title":"Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy","volume":"169","author":"Mitra","year":"2025","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"10.1016\/j.jtcvs.2024.10.040_bib9","first-page":"e1003","article-title":"A prospective clinical trial to evaluate mesothelin as a biomarker for the clinical management of patients with esophageal adenocarcinoma","volume":"278","author":"Byun","year":"2023","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.jtcvs.2024.10.040_bib10","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"}],"container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522324009929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522324009929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T23:56:47Z","timestamp":1742947007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022522324009929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0022522324009929"],"URL":"https:\/\/doi.org\/10.1016\/j.jtcvs.2024.10.040","relation":{},"ISSN":["0022-5223"],"issn-type":[{"type":"print","value":"0022-5223"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Commentary: Blood biomarkers: Barriers and benefits","name":"articletitle","label":"Article Title"},{"value":"The Journal of Thoracic and Cardiovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtcvs.2024.10.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtcvs.2024.10.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Association for Thoracic Surgery","name":"copyright","label":"Copyright"}]}}